JavaScript NENÍ povolen !

Prosím povolte JavaScript.

Článek

PubMed

Záznam pochází z PubMed

Impact of in vivo T-cell depletion on outcome of AML patients in first CR given peripheral blood stem cells and reduced-intensity conditioning allo-SCT from a HLA-identical sibling donor: a report from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation

Baron, F
Autor Baron, F Department of Hematology, University of Liège, Liège, Belgium
Labopin, M
Autor Labopin, M ] Clinical Hematology and Cellular Therapy Department, Hospital Saint Antoine, APHP, Paris, France [2] EBMT ALWP Office, Hospital Saint Antoine, Paris, France [3] Universite Pierre et Marie Curie, Paris, France [4] INSERM UMRs 938, Paris, France
Blaise, D
Autor Blaise, D Hematology, CHU de Marseille, Marseille, France
Lopez-Corral, L
Autor Lopez-Corral, L Hospital Clinico Universitario, Salamanca, Spain
Vigouroux, S
Autor Vigouroux, S Hematology, CHU de Bordeaux, Bordeaux, France
Craddock, C
Autor Craddock, C Centre for Clinical Haematology, Queen Elizabeth Hospital and School of Cancer Studies, University of Birmingham, Birmingham, UK
Attal, M
Autor Attal, M Hematology, CHU de Toulouse, Toulouse, France
Jindra, P
Autor Jindra, P Charles University Medical School and Teaching Hospital, Pilsen, Czech Republic
Goker, H
Autor Goker, H BMT Unit, Department of Hematology, Hacettepe University, Ankara, Turkey
Socié, G
Autor Socié, G Bone Marrow Transplantation, Saint-Louis Hospital, Paris, France
Chevallier, P
Autor Chevallier, P Hematology, CHU de Nantes, Nantes, France
Browne, P
Autor Browne, P Hope Directorate, St James's Hospital, Dublin, Ireland, UK
Sandstedt, A
Autor Sandstedt, A Department of Hematology, University Hospital, Linköping, Sweden
Duarte, R F
Autor Duarte, R F ICO-Hospital Duran i Reynals, l'Hospitalet de Llobregat, Barcelona, Spain
Nagler, A
Autor Nagler, A Hematology Division, Sheba medical Center, Tel-Aviv University, Tel-Hashomer, Israel
Mohty, M
Autor Mohty, M ] Clinical Hematology and Cellular Therapy Department, Hospital Saint Antoine, APHP, Paris, France [2] EBMT ALWP Office, Hospital Saint Antoine, Paris, France [3] Universite Pierre et Marie Curie, Paris, France [4] INSERM UMRs 938, Paris, France

Bone marrow transplantation. 2014 Mar ; 49 (3) : 389-96. [epub] 20140113

Bone Marrow Transplant
ISSN 1476-5365 | 0268-3369
Zdroj

Jazyk angličtina Země Velká Británie, Anglie Médium print-electronic

Typ dokumentu časopisecké články, multicentrická studie

Perzistentní odkaz https://www.medvik.cz/link/pmid24419525

PubMed 24419525
DOI 10.1038/bmt.2013.204
PII: bmt2013204
Knihovny.cz E-zdroje

MeSH
akutní myeloidní leukemie krev terapie MeSH
alemtuzumab MeSH
antilymfocytární sérum metabolismus MeSH
dárci tkání MeSH
dospělí MeSH
HLA antigeny imunologie MeSH
homologní transplantace MeSH
humanizované monoklonální protilátky terapeutické užití MeSH
incidence MeSH
indukce remise MeSH
kmenové buňky cytologie MeSH
lidé středního věku MeSH
lidé MeSH
melfalan terapeutické užití MeSH
mladý dospělý MeSH
multivariační analýza MeSH
nemoc štěpu proti hostiteli MeSH
přežití bez známek nemoci MeSH
příprava pacienta k transplantaci metody MeSH
proporcionální rizikové modely MeSH
recidiva MeSH
retrospektivní studie MeSH
senioři MeSH
sourozenci MeSH
T-lymfocyty cytologie MeSH
výsledek terapie MeSH
Check Tag
dospělí MeSH
lidé středního věku MeSH
lidé MeSH
mladý dospělý MeSH
mužské pohlaví MeSH
senioři MeSH
ženské pohlaví MeSH
Publikační typ
časopisecké články MeSH
multicentrická studie MeSH
Geografické názvy
Evropa MeSH
Názvy látek
alemtuzumab MeSH
antilymfocytární sérum MeSH
HLA antigeny MeSH
humanizované monoklonální protilátky MeSH
melfalan MeSH

The impact of in vivo T-cell depletion on transplantation outcomes in patients transplanted with reduced-intensity conditioning (RIC) remains controversial. This study assessed the outcome of 1250 adult patients with de novo AML in first CR (CR1) given PBSC from HLA-identical siblings after chemotherapy-based RIC. A total of 554 patients did not receive any form of in vivo T-cell depletion (control group), whereas antithymocyte globulin (ATG) and alemtuzumab were given in 444 and 252 patients, respectively. The incidences of grade II-IV acute GVHD were 21.4, 17.6 and 10.2% in control, ATG and alemtuzumab patients, respectively (P<0.001). In multivariate analysis, the use of ATG and the use of alemtuzumab were each associated with a lower risk of chronic GVHD (P<0.001 each), but a similar risk of relapse, and of nonrelapse mortality, and similar leukemia-free survival and OS. Further, among patients given BU-based RIC, the use of <6 mg/kg ATG did not increase the risk of relapse (hazard ratio, HR=1.1), whereas there was a suggestion for higher relapse risk in patients given 6 mg/kg ATG (HR=1.4, P=0.08). In summary, these data suggest that a certain amount of in vivo T-cell depletion can be safely used in the conditioning of AML patients in CR1 given PBSC after chemotherapy-based RIC.

] Clinical Hematology and Cellular Therapy Department Hospital Saint Antoine APHP Paris France [2] EBMT ALWP Office Hospital Saint Antoine Paris France [3] Universite Pierre et Marie Curie Paris France [4] INSERM UMRs 938 Paris France

BMT Unit Department of Hematology Hacettepe University Ankara Turkey

Bone Marrow Transplantation Saint Louis Hospital Paris France

Centre for Clinical Haematology Queen Elizabeth Hospital and School of Cancer Studies University of Birmingham Birmingham UK

Charles University Medical School and Teaching Hospital Pilsen Czech Republic

Department of Hematology University Hospital Linköping Sweden

Department of Hematology University of Liège Liège Belgium

Hematology CHU de Bordeaux Bordeaux France

Hematology CHU de Marseille Marseille France

Hematology CHU de Nantes Nantes France

Hematology CHU de Toulouse Toulouse France

Hematology Division Sheba medical Center Tel Aviv University Tel Hashomer Israel